AGRX — Agile Therapeutics Income Statement
0.000.00%
Last trade - 00:00- $10.43m
- $7.58m
- $19.59m
- 48
- 46
- 70
- 54
Annual income statement for Agile Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | R2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 0.749 | 4.1 | 10.9 | 19.6 |
| Cost of Revenue | |||||
| Gross Profit | — | 0.467 | -6.62 | 4.05 | 10.6 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 18.9 | 49.8 | 75.1 | 63.4 | 39.5 |
| Operating Profit | -18.9 | -49.1 | -71 | -52.6 | -19.9 |
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | -18.6 | -51.9 | -71.1 | -30.1 | -14.5 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -18.6 | -51.9 | -71.1 | -25.4 | -14.5 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -18.6 | -51.9 | -71.1 | -25.4 | -14.5 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -18.6 | -51.9 | -71.1 | -25.4 | -14.5 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -753 | -1,225 | -1,464 | -42.1 | -6.71 |